Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 12, 2006, Pages 5126-5129

  Yu, Run ^a   Bonert, Vivien ^a   Saporta, Inbar ^a   Raffel, Leslie J ^a   Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; GENOMIC DNA;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPOPHYSIS ADENOMA; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN INTERACTION; PROTEIN VARIANT; SCHOOL CHILD; UNITED STATES;

EID: 33845506431     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1731     Document Type: Article

References (15)

1. Melmed S 2003 Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603-1618
2. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S 1990 Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71:1427-1433
3. Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A 1990 Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 86:336-340
4. Yu R, Melmed S 2001 Oncogene activation in pituitary tumors. Brain Pathol 11:328-334
5. Alexander JM 2001 Tumor suppressor loss in pituitary tumors. Brain Pathol 11:342-355
6. Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji Y, Mateo C, Libutti SK, Oliver B, Chandrasekharappa SC, Burns AL, Collins FS, Spiegel AM, Marx SJ 2005 Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 37:369-374
7. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA 1992 Effects of an Rb mutation in the mouse. Nature 359:295-300
8. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA 2006 Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312: 1228-1230
9. Drange MR, Fram NR, Herman-Bonert V, Melmed S 2000 Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab 85:168-174
10. Carlson DB, Perdew GH 2002 A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 16:317-325
11. Kuzhandaivelu N, Cong YS, Inouye C, Yang WM, Seto E 1996 XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation. Nucleic Acids Res 24:4741-4750
12. Hollingshead BD, Petrulis JR, Perdew GH 2004 The aryl hydrocarbon (Ah) receptor transcriptional regulator hepatitis B virus X-associated protein 2 antagonizes p23 binding to Ah receptor-Hsp90 complexes and is dispensable for receptor function. J Biol Chem 279:45652-45661
13. Weiss C, Kolluri SK, Kiefer F, Gottlicher M 1996 Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor. Exp Cell Res 226:154-163
14. Kolluri SK, Weiss C, Koff A, Gottlicher M 1999 p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev 13:1742-1753
15. Peltonen L 1997 Molecular background of the Finnish disease heritage. Ann Med 29:553-556